Royalty Pharma PLC (RPRX) — SEC Filings

Q: What are the key financial highlights for Royalty Pharma PLC?

Key financial highlights for Royalty Pharma PLC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Royalty Pharma PLC?

Key executives at Royalty Pharma PLC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Royalty Pharma PLC stock?

Risk factors for Royalty Pharma PLC (RPRX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Royalty Pharma PLC?

Forward-looking statements and predictions from Royalty Pharma PLC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Royalty Pharma PLC. Recent 8-K filing on Apr 13, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Royalty Pharma PLC on SEC EDGAR

Overview

Royalty Pharma PLC (RPRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: Royalty Pharma plc announced a Regulation FD Disclosure on December 19, 2025. The filing, submitted on December 22, 2025, pertains to information that may be material to investors. The company's principal executive offices are located at 110 East 59th Street, New York, NY 10022.

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 3 bullish, 42 neutral, 1 mixed. The dominant filing sentiment for Royalty Pharma PLC is neutral.

Filing Type Overview

Royalty Pharma PLC (RPRX) has filed 28 8-K, 6 10-Q, 3 DEFA14A, 2 10-K, 5 SC 13G/A, 1 SC 13D/A, 1 DEF 14A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (46)

8-K Filing — 8-K · Apr 13, 2026
Royalty Pharma plc Files 8-K for Regulation FD Disclosure — 8-K · Dec 22, 2025 Risk: low
Royalty Pharma plc announced a Regulation FD Disclosure on December 19, 2025. The filing, submitted on December 22, 2025, pertains to information that may be ma
Royalty Pharma's Q3 Net Income Dips Amid Soaring R&D, G&A Costs — 10-Q · Nov 5, 2025 Risk: medium
Royalty Pharma plc (RPRX) reported a consolidated net income of $968.279 million for the nine months ended September 30, 2025, a decrease from $996.462 million
Royalty Pharma plc Files 8-K: Material Agreement & Financials — 8-K · Sep 16, 2025 Risk: medium
On September 16, 2025, Royalty Pharma plc entered into a material definitive agreement. The filing also indicates other events and the submission of financial s
Royalty Pharma plc Files 8-K on Executive Changes — 8-K · Aug 13, 2025 Risk: low
Royalty Pharma plc filed an 8-K on August 13, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of c
Royalty Pharma plc Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
On August 6, 2025, Royalty Pharma plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as
Royalty Pharma's Q2 Royalties Surge 27% to $1.25B — 10-Q · Aug 6, 2025 Risk: medium
Royalty Pharma plc reported strong financial performance for the six months ended June 30, 2025, with total royalty receipts from financial royalty assets reach
Royalty Pharma plc Files 8-K on Executive Changes and Financials — 8-K · Jul 17, 2025 Risk: low
Royalty Pharma plc filed an 8-K on July 17, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of cer
Royalty Pharma plc Files 8-K: Agreements, Acquisitions, and Executive Changes — 8-K · May 19, 2025 Risk: medium
On May 16, 2025, Royalty Pharma plc entered into a material definitive agreement related to the creation of a direct financial obligation. The company also comp
Royalty Pharma plc Files 8-K on Security Holder Vote — 8-K · May 12, 2025 Risk: low
On May 12, 2025, Royalty Pharma plc filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific d
Royalty Pharma plc Files 8-K for Operations Update — 8-K · May 8, 2025 Risk: low
Royalty Pharma plc filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibits. Th
Royalty Pharma plc Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter o
Royalty Pharma plc Files 8-K — 8-K · Apr 11, 2025 Risk: medium
On April 11, 2025, Royalty Pharma plc entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counte
Royalty Pharma PLC Reports Director Changes and Compensation Updates — 8-K · Apr 10, 2025 Risk: low
Royalty Pharma plc announced on April 7, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depa
Royalty Pharma Files Preliminary Proxy for Deal — DEFA14A · Mar 5, 2025 Risk: medium
Royalty Pharma plc filed a DEFA14A on March 5, 2025, related to preliminary proxy materials for a proposed transaction. This filing indicates that the company i
Royalty Pharma plc Files 2024 10-K — 10-K · Feb 12, 2025 Risk: low
Royalty Pharma plc filed its 2024 10-K on February 12, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in New York, oper
Royalty Pharma plc Files 8-K for Financial Reporting — 8-K · Feb 11, 2025 Risk: low
Royalty Pharma plc filed an 8-K on February 11, 2025, to report on its results of operations and financial condition, as well as to file financial statements an
Royalty Pharma Preps Proxy for Key Transaction — DEFA14A · Jan 17, 2025 Risk: low
Royalty Pharma plc filed a DEFA14A, indicating it is soliciting materials prior to furnishing a definitive proxy statement for a proposed transaction. The filin
Royalty Pharma plc Files Proxy Statement for Proposed Transaction — DEFA14A · Jan 16, 2025 Risk: low
Royalty Pharma plc is filing a DEFA14A, indicating it is soliciting materials prior to furnishing a definitive proxy statement for a proposed transaction. The f
Royalty Pharma plc Files Form 8-K — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, Royalty Pharma plc (RPRX) filed a Form 8-K to report its current status. The filing confirms the company's principal executive offices are
Royalty Pharma plc Files 8-K for Financial Reporting — 8-K · Jan 10, 2025 Risk: low
Royalty Pharma plc filed an 8-K on January 10, 2025, to report on its results of operations and financial condition, as well as to file financial statements and
Royalty Pharma plc (RPRX) Files 8-K — 8-K · Jan 10, 2025 Risk: low
On January 10, 2025, Royalty Pharma plc (RPRX) filed an 8-K report. The filing confirms the company's principal executive offices are located at 110 East 59th S
Royalty Pharma Files 8-K on Material Agreements — 8-K · Dec 31, 2024 Risk: low
Royalty Pharma plc filed an 8-K on December 31, 2024, reporting on a material definitive agreement, amendments to its articles of incorporation or bylaws, and f
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
Royalty Pharma Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
Royalty Pharma plc filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
Royalty Pharma Q3 Revenue Rises to $644M — 10-Q · Nov 6, 2024 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending September 30, 2024. The company's financial royalty assets generated $644 million in the third quarter o
Royalty Pharma Buys Pfizer Royalty for $2.25B — 8-K · Sep 27, 2024 Risk: medium
Royalty Pharma plc announced on September 26, 2024, that it has entered into a definitive agreement to acquire a royalty interest in certain products from Pfize
Royalty Pharma plc Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
Royalty Pharma plc filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibi
Royalty Pharma plc Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: low
Royalty Pharma plc filed its 10-Q for the period ending June 30, 2024. The company's financial statements and disclosures for the second quarter and first half
Royalty Pharma plc Files 8-K Report — 8-K · Aug 7, 2024 Risk: low
On August 6, 2024, Royalty Pharma plc filed an 8-K report to disclose information under Regulation FD. The filing confirms the company's principal executive off
Royalty Pharma SC 13D/A Amendment Filed — SC 13D/A · Jul 29, 2024 Risk: medium
On July 29, 2024, Royalty Pharma plc filed an amendment (No. 4) to its Schedule 13D. The filing indicates changes in beneficial ownership by a group including A
Royalty Pharma Buys J&J Tremfya Royalties for $500M — 8-K · Jun 20, 2024 Risk: medium
On June 17, 2024, Royalty Pharma plc announced the closing of its acquisition of a portion of the future royalty rights on Tremfya (guselkumab) from Johnson & J
Royalty Pharma plc Files 8-K: Material Agreement & Financial Obligations — 8-K · Jun 10, 2024 Risk: medium
On June 10, 2024, Royalty Pharma plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or a
Royalty Pharma plc Files 8-K on Security Holder Votes — 8-K · Jun 6, 2024 Risk: low
Royalty Pharma plc filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the
Royalty Pharma plc Files 8-K for Material Definitive Agreement — 8-K · Jun 4, 2024 Risk: medium
On June 3, 2024, Royalty Pharma plc entered into a material definitive agreement. The company, headquartered at 110 East 59th Street, New York, NY, filed an 8-K
Royalty Pharma plc Files 8-K Report — 8-K · May 29, 2024 Risk: low
On May 29, 2024, Royalty Pharma plc filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material transactions o
Royalty Pharma plc Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
Royalty Pharma plc filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exh
Royalty Pharma plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
Royalty Pharma plc (RPRX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Royalty Pharma plc filed its quarterly report (10-Q) on May 9, 2024, for
DEF 14A Filing — DEF 14A · Apr 25, 2024
Royalty Pharma plc Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk:
Royalty Pharma plc (RPRX) filed a Annual Report (10-K) with the SEC on February 15, 2024. Royalty Pharma plc filed its 2023 Form 10-K on February 15, 2024. The
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
FMR LLC & Abigail Johnson Trim Royalty Pharma Stake to 7.099% — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Royalty Pharma plc. As of February 9, 2024,
Morgan Stanley Amends Royalty Pharma Stake (SC 13G/A) — SC 13G/A · Feb 9, 2024 Risk: low
Morgan Stanley filed an amended Schedule 13G/A on February 9, 2024, indicating its ownership of Class A Ordinary Shares in Royalty Pharma plc as of December 31,
Royalty Pharma Files 8-K for 'Other Event' on Feb 5, 2024 — 8-K · Feb 6, 2024
Royalty Pharma plc filed an 8-K on February 6, 2024, reporting an "Other Event" that occurred on February 5, 2024. This filing, under Item 8.01, indicates a rou
Royalty Pharma Files 8-K on Financial Results, Exhibits — 8-K · Jan 8, 2024
Royalty Pharma plc filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' Th

Risk Profile

Risk Assessment: Of RPRX's 38 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Royalty Pharma PLC's most recent 10-Q filing (Nov 5, 2025):

Revenue: $1,756,203,000
Net Income: $968,279,000
EPS: $1.29
Debt-to-Equity: 1.01
Cash Position: $938,944,000
Operating Margin: 7.0%
Total Assets: $19,347,280,000
Total Debt: $8,945,735,000

Key Executives

Achille G. Severgnini
Juan Francisco Mendez, Esq.
Abigail P. Johnson

Industry Context

Royalty Pharma operates in the pharmaceutical and biotechnology sector, focusing on acquiring and investing in royalty interests. The industry is characterized by high R&D costs, long development cycles, patent cliffs, and significant regulatory oversight. Companies like Royalty Pharma provide crucial capital to drug developers in exchange for future revenue streams, navigating a landscape of innovation, competition, and patent expirations.

Top Tags

financial-reporting (9) · sec-filing (8) · 8-k (7) · corporate-governance (4) · material-agreement (3) · financials (3) · material-definitive-agreement (3) · 10-Q (3) · proxy-statement (3) · disclosure (2)

Key Numbers

Consolidated Net Income: $968.279M — Decreased from $996.462M in 2024 for the nine months ended September 30.
Income from Financial Royalty Assets: $1,668.720M — Increased from $1,587.577M in 2024 for the nine months ended September 30.
Research and Development Funding Expense: $401.500M — Massive increase from $1.500M in 2024 for the nine months ended September 30.
General and Administrative Expenses: $409.209M — Increased from $169.080M in 2024 for the nine months ended September 30.
Provision for Credit Losses on Unfunded Commitments: $93.301M — Increased from zero in 2024 for the nine months ended September 30.
Long-term Debt: $8,565.735M — Increased from $6,614.653M at December 31, 2024.
Basic EPS (Q3 2025): $0.67 — Decreased from $1.22 in Q3 2024.
Basic EPS (YTD 2025): $1.29 — Decreased from $1.45 in YTD 2024.
Cash and Cash Equivalents: $938.944M — Slight increase from $929.026M at December 31, 2024.
Total Assets: $19,347.280M — Increased from $18,222.715M at December 31, 2024.
Royalty Receipts (6 months): $1.25B — Increased from $1.05B in prior-year period, showing strong growth.
Q2 Net Income: $280M — Up 27.3% from $220M in Q2 2024, indicating significant profitability growth.
Net Income Growth: 27.3% — Percentage increase in net income attributable to common stockholders from Q2 2024 to Q2 2025.
Quarterly Dividend: $0.20 — Declared per Class A ordinary share, demonstrating commitment to shareholder returns.
SEC File Number: 001-39329 — Identifies the company's filing history with the SEC.

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Royalty Pharma plc.","entity":"FMR LLC","targetDate":"next 12 months","confidence":"high"}

Related Companies

JNJ

Frequently Asked Questions

What are the latest SEC filings for Royalty Pharma PLC (RPRX)?

Royalty Pharma PLC has 46 recent SEC filings from Jan 2024 to Apr 2026, including 28 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of RPRX filings?

Across 46 filings, the sentiment breakdown is: 3 bullish, 42 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Royalty Pharma PLC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Royalty Pharma PLC (RPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Royalty Pharma PLC?

Key financial highlights from Royalty Pharma PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for RPRX?

The investment thesis for RPRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Royalty Pharma PLC?

Key executives identified across Royalty Pharma PLC's filings include Achille G. Severgnini, Juan Francisco Mendez, Esq., Abigail P. Johnson.

What are the main risk factors for Royalty Pharma PLC stock?

Of RPRX's 38 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 27 low-risk.

What are recent predictions and forward guidance from Royalty Pharma PLC?

Recent forward-looking statements from Royalty Pharma PLC include guidance on {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Royalty Pharma plc.","entity":"F.